Free Trial

BioVie (BIVI) Stock Forecast & Price Target

$0.42
+0.01 (+2.84%)
(As of 08:32 AM ET)

BioVie - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$6.33
1,405.79% Upside
High Forecast$11.00
Average Forecast$6.33
Low Forecast$3.00
TypeCurrent Forecast
7/9/23 to 7/8/24
1 Month Ago
6/9/23 to 6/8/24
3 Months Ago
4/10/23 to 4/9/24
1 Year Ago
7/9/22 to 7/9/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.33$8.00$8.00$9.00
Forecasted Upside1,405.79% Upside236.61% Upside236.61% Upside179.21% Upside

BIVI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BIVI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioVie Stock vs. The Competition

TypeBioVieMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside1,448.49% Upside1,005.50% Upside12.25% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/1/2024ThinkEquity
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00+649.05%
11/30/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
11/30/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$12.00 ➝ $5.00+174.72%
9/28/2022EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$14.00 ➝ $8.00+218.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:24 AM ET.

BIVI Forecast - Frequently Asked Questions

What is BioVie's forecast for 2024?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for BioVie is $6.33, with a high forecast of $11.00 and a low forecast of $3.00.

Should I buy or sell BioVie stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioVie in the last year. There is currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIVI shares.

Does BioVie's stock price have much upside?

According to analysts, BioVie's stock has a predicted upside of 299.28% based on their 12-month stock forecasts.

What analysts cover BioVie?

BioVie has been rated by research analysts at ThinkEquity in the past 90 days.

Do Wall Street analysts like BioVie more than its competitors?

Analysts like BioVie less than other "medical" companies. The consensus rating score for BioVie is 2.67 while the average consensus rating score for "medical" companies is 2.71. Learn more on how BIVI compares to other companies.


This page (NASDAQ:BIVI) was last updated on 7/8/2024 by MarketBeat.com Staff

From Our Partners